This clinical trial evaluates whether the Empower Latinx intervention improves knowledge and uptake of lung cancer screening among Hispanic patients who are eligible for lung cancer screening. The Hispanic community remains one of the most underserved populations with sub-optimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer-related mortality, and Hispanic patients are known to have lower survival rates compared with non-Hispanic whites. The Empower Latinx intervention may improve lung cancer screening rates among Hispanic patients by addressing patient knowledge and barriers to care.
Additional locations may be listed on ClinicalTrials.gov for NCT06225414.
Locations matching your search criteria
United States
California
Orange
UC Irvine Health/Chao Family Comprehensive Cancer CenterStatus: Active
Contact: Gelareh Sadigh
Phone: 714-456-3610
PRIMARY OBJECTIVE:
I. Assess lung cancer screening (LCS)-eligible Hispanic patients’ perceptions and barriers toward LCS.
SECONDARY OBJECTIVES:
I. Assess the feasibility of Empower Latinx in increasing Hispanic patients’ LCS knowledge, having a low dose computed tomography of the chest (LDCT) ordered, and receipt of LCS with LDCT and compare its effectiveness with enhanced usual care.
II. Describe Hispanic patients’ & providers’ experience with an intervention using a mixed-methods approach.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive usual care including a provider flag in their electronic medical record (EMR) denoting eligibility for LCS, and also receive brief education material on LCS benefits and risk.
ARM B: Patients receive usual care in addition to the Empower Latinx intervention, which includes primary care provider (PCP) notification of patient's eligibility for LCS and their self-reported barriers to LCS, education on lung cancer risk, LCS benefits, harms, false positive rates, recommendations for follow up procedures, and insurance coverage, a patient referral to financial navigation resources, and a patient reminder to discuss LCS during their upcoming visit with their PCP.
After completion of study intervention, patients are followed up at 4 months.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUC Irvine Health/Chao Family Comprehensive Cancer Center
Principal InvestigatorGelareh Sadigh
